We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
101
Instil Bio
TIL
$49.4M
$605K 0.12%
31,708
+8,001
+34% +$244K
OGN icon
102
Organon & Co
OGN
$3.56B
$600K 0.12%
40,200
+37,100
+1,197% +$605K
SLDB icon
103
Solid Biosciences
SLDB
$857M
$596K 0.12%
148,903
-996,689
-87% -$5.47M
ONC
104
BeOne Medicines Ltd
ONC
$36.7B
$549K 0.11%
2,974
+1,996
+204% +$408K
USFR icon
105
WisdomTree Floating Rate Treasury Fund
USFR
$18.4B
$503K 0.1%
10,000
– –
VRDN icon
106
Viridian Therapeutics
VRDN
$2.49B
$498K 0.1%
26,000
+16,794
+182% +$365K
SDGR icon
107
Schrodinger
SDGR
$1.33B
$485K 0.1%
+25,147
New +$488K
APLS
108
DELISTED
Apellis Pharmaceuticals
APLS
$479K 0.1%
15,000
-2,252
-13% -$67.7K
VIR icon
109
Vir Biotechnology
VIR
$1.48B
$470K 0.09%
64,067
-255,118
-80% -$2.01M
BIIB icon
110
Biogen
BIIB
$30.5B
$466K 0.09%
3,045
-26,580
-90% -$4.48M
APLT
111
CALL
DELISTED
Applied Therapeutics
APLT
$454K 0.09%
530,324
+124
+0% +$777
PHAT icon
112
Phathom Pharmaceuticals
PHAT
$679M
$450K 0.09%
55,400
+55,200
+27,600% +$684K
NETD
113
DELISTED
Nabors Energy Transition Corp II
NETD
$431K 0.09%
39,900
-20,000
-33% -$214K
AKRO
114
DELISTED
Akero Therapeutics
AKRO
$426K 0.09%
15,307
-7,700
-33% -$233K
CMRX
115
DELISTED
Chimerix, Inc.
CMRX
$425K 0.09%
122,236
-118,321
-49% -$167K
ABSI icon
116
Absci
ABSI
$1.41B
$413K 0.08%
157,665
-848,085
-84% -$2.99M
KYMR icon
117
Kymera Therapeutics
KYMR
$8.75B
$402K 0.08%
10,000
-1,856
-16% -$83.8K
DNTH icon
118
Dianthus Therapeutics
DNTH
$6.15B
$385K 0.08%
17,683
-101,055
-85% -$2.6M
VKTX icon
119
Viking Therapeutics
VKTX
$3.88B
$374K 0.07%
9,300
+2,200
+31% +$125K
MRNA icon
120
Moderna
MRNA
$21.5B
$374K 0.07%
+9,000
New +$430K
CNTX icon
121
Context Therapeutics
CNTX
$46.3M
$369K 0.07%
351,094
-22,741
-6% -$39.4K
AVIR icon
122
Atea Pharmaceuticals
AVIR
$399M
$369K 0.07%
+110,000
New +$366K
KROS icon
123
Keros Therapeutics
KROS
$211M
$368K 0.07%
23,246
-421,822
-95% -$21.9M
ANAB icon
124
AnaptysBio
ANAB
$1.62B
$361K 0.07%
27,301
-165,419
-86% -$4.01M
VTGN icon
125
VistaGen Therapeutics
VTGN
$12.6M
$358K 0.07%
121,461
-41,617
-26% -$117K
3 4
5
6 7

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.